Anemia-Related Survival of Patients with Myelofibrosis: A Retrospective Real-World Study
Author(s)
Gabriela Abreu, PhD1, Juliana Queiroz, MSc1, Thiago Luiz Nogueira Silva, PhD1, Claudia Soares, PhD, MHP, MD1, Patricia Menezes Rezende, MBA1, Tatiana Pires, PhD1, Straus Tanaka, MSc1, Graziela Bernardino, MBA1, Lucas Perelli, MSc, MD2, Mariano Carrizo, PhD2, Paula Scibona, MD3, Delfina Recart, MD3, Ventura Alejandro Simonovich, MD3, Georgina Bendek Del Prete, MD3, Veronica Privitera, MD3, Fernandes Taís Bertoldo Teixeira, PharmD4, Michel Lima de Moraes, BSc4, Robson Bruniera de Oliveira, PhD4.
1GSK, Rio de Janeiro, Brazil, 2GSK, Buenos Aires, Argentina, 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Orizon, São Paulo, Brazil.
1GSK, Rio de Janeiro, Brazil, 2GSK, Buenos Aires, Argentina, 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Orizon, São Paulo, Brazil.
OBJECTIVES: Hematological Impact in Myelofibrosis in Emerging Markets (HeIIM), a real-world study on myelofibrosis (MF), aims to evaluate practices and clinical outcomes in Latin America. This analysis focuses on survival data by anemia status due to its considerable impact and the scarcity of this information in the region.
METHODS: HeIIM used private insurance data in Argentina (2010-2022) and Brazil (2015-2022) from patients ≥18 years with ≥1 MF-related term/ICD-10 code (D47.1/C94.5). The first date of the term/ code was considered the MF index date (proxy for diagnosis). Patients were followed until death/loss to follow-up. Anemia was classified (before index or during follow-up) based on hemoglobin level (when available), presence of ≥2 anemia-related codes and/or anemia-related medication and/or red blood cell transfusion. Overall survival curves (Kaplan-Meier) were split by anemia status.
RESULTS: In Argentina, 228 patients with MF were included; mean (standard deviation [SD]) age and follow-up duration were 68 (14) years and 37.4 (35.8) months, respectively, and 52.6% had anemia. During follow-up, 67 (29.4%) patients died, 63 of whom had anemia. Overall adjusted median survival time was 96.1 months (anemia: 61.4 months; without anemia: not reached). Five-year survival rate was 66.7% (overall): 52.0% with anemia and 92.6% without. In Brazil, 334 patients were included; mean (SD) age and follow-up duration were 62 (19) years and 20.5 (20.2) months, respectively, and 55.4% had anemia. During follow-up, 82 (24.6%) patients died, 67 of whom had anemia. Overall adjusted median survival time was 55.5 months (anemia: 41.1 months; without anemia: not reached). Five-year survival rate was 47.1% (overall): 35.3% with anemia and 68.8% without.
CONCLUSIONS: Patients with concomitant anemia have a poorer prognosis than the overall MF patient population in Latin America. This highlights the importance of addressing anemia in these patients and suggests potential regional disparities in outcomes warrant investigation.
METHODS: HeIIM used private insurance data in Argentina (2010-2022) and Brazil (2015-2022) from patients ≥18 years with ≥1 MF-related term/ICD-10 code (D47.1/C94.5). The first date of the term/ code was considered the MF index date (proxy for diagnosis). Patients were followed until death/loss to follow-up. Anemia was classified (before index or during follow-up) based on hemoglobin level (when available), presence of ≥2 anemia-related codes and/or anemia-related medication and/or red blood cell transfusion. Overall survival curves (Kaplan-Meier) were split by anemia status.
RESULTS: In Argentina, 228 patients with MF were included; mean (standard deviation [SD]) age and follow-up duration were 68 (14) years and 37.4 (35.8) months, respectively, and 52.6% had anemia. During follow-up, 67 (29.4%) patients died, 63 of whom had anemia. Overall adjusted median survival time was 96.1 months (anemia: 61.4 months; without anemia: not reached). Five-year survival rate was 66.7% (overall): 52.0% with anemia and 92.6% without. In Brazil, 334 patients were included; mean (SD) age and follow-up duration were 62 (19) years and 20.5 (20.2) months, respectively, and 55.4% had anemia. During follow-up, 82 (24.6%) patients died, 67 of whom had anemia. Overall adjusted median survival time was 55.5 months (anemia: 41.1 months; without anemia: not reached). Five-year survival rate was 47.1% (overall): 35.3% with anemia and 68.8% without.
CONCLUSIONS: Patients with concomitant anemia have a poorer prognosis than the overall MF patient population in Latin America. This highlights the importance of addressing anemia in these patients and suggests potential regional disparities in outcomes warrant investigation.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EPH166
Topic
Epidemiology & Public Health
Topic Subcategory
Disease Classification & Coding
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology